Showing 2561-2570 of 3738 results for "".
Dr. Garden Discusses Experience with the VariLite Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-garden-discusses-experience-with-gemini-laser/19467/"The VariLite system is a wonderful choice for those people who want to enter into the laser arena. Because many, many patients have vessels which naturally occur as they grow older or especially those who develop rosacea later in life, this is something that many practices have the need for treatDermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiRhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-rhatigan-to-merz-moc-dissatisfaction-syneron-candela-sale/18485/Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of SyDigital Innovation to the Rescue: The Future of Electronic Prior Authorization in Dermatology
https://practicaldermatology.com/topics/practice-management/digital-innovation-to-the-rescue-the-future-of-electronic-prior-authorization-in-dermatology/20467/Adopting new technology to reduce paperwork, costs, and burnout as well as improve patient care.Updating Approaches to Psoriasis
https://practicaldermatology.com/topics/psoriasis/evaluating-the-state-of-psoriasis-care/21660/Recent guidelines from the National Psoriasis Foundation point to new directions in research and therapy that will continue to shape psoriasis therapy.Overcoming Real and Perceived Challenges in Medical Management of Actinic Keratoses
https://practicaldermatology.com/topics/general-topics/overcoming-real-and-perceived-challenges-in-medical-management-of-actinic-keratoses/21845/Everyone from prescribers to patients to pharmacists plays a role in the successful incorporation of medical AK management.Taking the Pulse of Device-based Aesthetics Procedures
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/taking-the-pulse-of-device-based-aesthetics-procedures/22956/With new developments in store, the evolution of devices for aesthetic procedures is creating new possibilities.Rediscovering Topical Antifungal Therapy for Onychomycosis
https://practicaldermatology.com/topics/hair-nails/rediscovering-topical-antifungal-therapy-for-onychomycosis/22974/A number of potential topical therapies for onychomycosis have failed clinical investigation. Do we at last have a viable alternative to oral treatment options?An Overview of Topical Therapies for Managing Pediatric AD
https://practicaldermatology.com/topics/atopic-dermatitis/an-overview-of-topical-ththerapies-for-managing-pediatric-ad/54375/Moisturization is foundational in AD management; no specific formulation has demonstrated superiority, and excessive bathing may worsen disease via increased transepidermal water loss. Topical corticosteroids and calcineurin inhibitors remain first-line due to strong efficacy data, cost-effectivene